Skip to content

Oxidation-reduction Homeostasis in Cognitive Impairment Patients After Stroke

Effects of Oxidation-reduction Homeostasis on Cognitive Impairment in Patients With Ischemic Stroke

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03519828
Enrollment
100
Registered
2018-05-09
Start date
2018-03-01
Completion date
2019-01-01
Last updated
2019-07-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oxidative-reduction Homeostasis, Post-stroke Cognitive Impairment

Brief summary

Cognitive impairment after ischemic stroke can affect not only the social adaptation ability, but also affect the comprehensive rehabilitation of patients. The damage of cognitive impairment after ischemic stroke is not lower than the body function defect after stroke. Many studies have shown that oxidative stress is one of the pathophysiological mechanisms of ischemic cerebrovascular disease. Many studies have reported that the oxidative-reduction of cells plays an important role in the life activities of organisms, affecting the health, aging and death of the organism. In the recent years, some scholars have suggested that post-stroke cognitive impairment may be related to oxidative-reduction homeostasis of the body, but the relevant evidence is lacking and needs to be further explored. Therefore, the purpose of this study is to explore the effect of oxidation-reduction homeostasis on cognitive impairment in patients with ischemic stroke, and provide a theoretical basis for the prevention and treatment of cognitive impairment after ischemic stroke.

Interventions

OTHERNo intervention has been conducted

It is an observational study, and no intervention has been conducted

Sponsors

Hui-Sheng Chen
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
40 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* 40-80 years old; * Ischemic stroke for the first time or previous stroke but with no serious sequelae (mRS is 0 -2 points); * Time from onset to treatment ≤48 hours; * Conscious awareness, and with no obvious aphasia and visual impairment; * Signed informed consent by patient self or legally authorized representatives.

Exclusion criteria

* Intracranial hemorrhage or suspected subarachnoid hemorrhage; * Transient ischemic attack; * Patients with severe mental disorders or language disorders; * Patients can not cooperate with evaluators, such as mental illness or dementia; * Pregnant women or suckers; * Researchers consider patients inappropriate to participate in the registry.

Design outcomes

Primary

MeasureTime frameDescription
Oxidative-reduction homeostasis in acute ischemic stroke patients1 dayReduced glutathione (GSH)/ Oxidized glutathione (GSSG), Superoxide dismutase (SOD), Catalase (CAT), Glutathione Peroxidase (GSH-PX) of acute ischemic stroke patients will be tested.
Cognitive function in acute ischemic stroke patients1 dayMini Mental Status Examination (MMSE) and Montreal cognitive assessment scale (MoCA) in acute ischemic stroke patients will be evaluated.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 28, 2026